LB Pharmaceuticals Inc Common Stock (LBRX)
LB Pharmaceuticals Inc Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in New York, NY, US. The stock last traded at $45.33, down 1.13% on the session, giving a market capitalisation of $1.30B. On trailing twelve-month figures it carries a trailing P/E of -2.11, a net margin of 0.0%. Its beta of 0.42 implies it has historically moved less than the broad market.
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
LB Pharmaceuticals Inc Common Stock is most often compared with the following Healthcare names: